Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles & Nanoparticle-based Therapeutics Europe 2023

Chiara Pretto's Biography



Chiara Pretto, Senior Scientist, Process Development, Ardena Nanomedicines

Chiara Pretto received her M.Sc. in Chemistry and Pharmaceutical Technology at the University of Padua. After performing an industrial internship at the Philochem Company, she enrolled in OcuTher (Horizon 2020 Marie Sklodowska-Curie Actions Innovative Training Networks) to carry out her PhD within the research group of Prof. Jan van Hest at the Eindhoven University of Technology. She performed several secondments in different research groups such as 20Med Therapeutics, the University of Eastern Finland, the University of Helsinki and the Queen’ s University of Belfast. After obtaining her PhD in Biomedical engineering, she joined Ardena Oss in 2021. She is currently working as Group Lead of the Process R&D Nanomedicines. Her expertise lies in the development of nanoparticles and their scale-up processes, therefore leading a group of scientists towards process development and large-scale (GMP-)manufacturing of nanomedicines for (pre)clinical trial applications, ensuring effective translation from laboratory concepts to real-world applications.

Chiara Pretto Image

Scale-up Development and Manufacturing of Nanomedicines: From Tech Transfer to Clinical Batch

Tuesday, 14 November 2023 at 11:00

Add to Calendar ▼2023-11-14 11:00:002023-11-14 12:00:00Europe/LondonScale-up Development and Manufacturing of Nanomedicines: From Tech Transfer to Clinical BatchExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Nanomedicines represent the cutting-edge frontier in the pharmacological field, providing unique solutions for the treatment of various diseases as well as for imaging purposes. The rapid advancement in this field poses significant challenges to clinical development and requires a carefully planned development scheme executed by scientists experienced in nanoparticle synthesis and characterization. As a contract development and manufacturing organization at the forefront of the nanomedicine landscape, Ardena embraces these challenges and can provide fine-tuning of manufacturing techniques, development of tailor-made reproducible, scalable, and GMP-amenable processes as well as full characterization of products. We will present how we navigate our customer’s lead nanomedicines through drug development, and we will highlight some of the challenges in bringing nanoparticles-based therapeutics from discovery to the clinic.


Add to Calendar ▼2023-11-13 00:00:002023-11-14 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023Extracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com